Proteome Sciences plc PMSNF OTC · Healthcare · United Kingdom
$0.01 +0.00% +$0.00
Summary
26 / 100 · Bulios Score
What speaks for it
- The price moves less than the market (beta 0.15).
What to watch
- Revenue fell by 21% a year over the last 3 years.
- The company made a loss over the last 12 months.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (GBP)
Diluted EPS (GBP)
- Analyst estimate
Revenue fell by 4.5% a year over 5 years. Over the last 3 years it fell by 21% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of £2.32M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 43.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.